HER2 mAb Fc構造と結合エネルギーに対するPEG鎖長効果のマルチスケール計算研究

HER2 overexpression in breast cancer drives aggressive disease, treated clinically with monoclonal antibodies such as trastuzumab and pertuzumab. While effective, these therapies are limited by suboptimal pharmacokinetics and tumor penetration. Polyethylene glycol (PEG) conjugation can extend circulation half-life but may alter Fc-mediated interactions and receptor binding. Here, we used a multiscale computational framework to quantify PEGylation effects on the pertuzumab Fc domain. Structural models were generated with AlphaFold2, refined with RoseTTAFold2 to incorporate G0F-type glycans at Asn297, and site-specifically PEGylated via hydrazone linkages in UCSF ChimeraX. Aglycosylated control and PEGylated variants (1, 2, and 4 kDa) underwent 100 ns all-atom molecular dynamics simulations in GROMACS. Increasing PEG size produced stepwise RMSD elevations (1.1-13 nm) and hinge expansion (21.37-63.53 Å). RMSF analysis revealed domain-specific mobility shifts within the Fc region: CH2 flexibility in the control, CH3 mobility in the 1 and 2 kDa variants, and CH2/CH3 destabilization (>2.0 nm) in the 4 kDa system. Principal component analysis showed PC1 (45-70% variance) capturing hinge-closing and CH2 inward motion in controls, versus CH3 separation and CH2-CH3 displacement in PEGylated forms; the 4 kDa variant exhibited pronounced flexibility (PC2 ∼20 to 25%). Complementary backbone dihedral and hydrogen bond analyses showed localized torsional relaxation and a reduction in CH2-CH3 hydrogen bond occupancy in PEGylated systems, confirming the structural basis of hinge expansion. Vector projections indicated steric and entropic disruption of interdomain hydrogen bonds, suggesting reduced Fcγ receptor engagement. These results reveal PEG size-dependent structural perturbations, providing a molecular basis for diminished HER2 affinity and guiding rational design of PEGylated mAbs with optimized pharmacokinetics and preserved effector function.